We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds

By LabMedica International staff writers
Posted on 09 Feb 2024

Fentanyl, a synthetic opioid recognized by the Centers for Disease Control and Prevention as being 50 times more potent than heroin and 100 times more potent than morphine, is often illicitly combined with other drugs. More...

Just 2 milligrams of fentanyl, roughly equivalent to 10 to 15 grains of table salt, can be fatal. Daily, over 150 people succumb to overdoses involving synthetic opioids such as fentanyl. Research has shown that fentanyl can be detected in urine up to 72 hours after use. Now, researchers have developed a first-of-its-kind, handheld device that is capable of accurately detecting fentanyl in urine within seconds.

The device developed by researchers at University of Texas at Dallas (Richardson, TX, USA) contains an electrochemical sensor that operates by generating electrical signals from chemical reactions. Detecting fentanyl was challenging due to its nonvolatile nature, meaning it doesn't naturally produce an electrochemical signature. To overcome this, the researchers designed a molecular cage-like structure resembling a mousetrap to capture fentanyl. This "trap" incorporates several components, including gold nanoparticles, and utilizes naloxone, a medication that reverses opioid overdoses, to attract and bind to fentanyl. When a urine sample is applied to a test strip, the presence of fentanyl triggers a reaction with the naloxone, resulting in a detectable signal.

This technology can also test other substances for fentanyl by simply diluting a sample in water and applying it to the sensor. The team's proof-of-concept device can detect trace amounts of fentanyl with 98% accuracy, bypassing the need for expensive and time-consuming lab analyses. The current prototype, designed for urine testing, is a precursor to developing a saliva-based test. Efforts are underway to expand the technology for detecting fentanyl in hair, with the ultimate goal being a saliva test. A saliva-based test would be particularly beneficial for first responders in making timely treatment decisions for overdose cases.

“There is an urgent demand for an easy-to-use, portable, miniaturized device that can detect fentanyl with high specificity and share results immediately to an internet-connected device,” said Dr. Shalini Prasad, professor and department head of bioengineering in the Erik Jonsson School of Engineering and Computer Science. “Our study demonstrates the feasibility of a highly accurate sensor to detect fentanyl within seconds.”

Related Links:
University of Texas at Dallas


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Automatic CLIA Analyzer
Shine i6000
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.